The pacemaker market (electrotherapy of bradycardia or heart failure) size is accounted for $15 billion USD.
Current pacemaker treatment uses a method of placing a lead on the apical right ventricle and applying electrical stimulation, which has a serious disadvantage of (1) heart failure due to a delay in ventricular electrical conduction (wide QRS) (2) tricuspid regurgitation (20-30%).
[Limits of Conventional Pacemaker Therapy]
To overcome these shortcomings, there are His bundle pacing (HBP) that provides electrical stimulation by placing a lead in His bundle, the electrical conduction system of the ventricle, or CRT that performs biventricular pacing by applying stimulation from two ventricles. However, both methods are not easy to apply because the procedure is not convenient and expensive (2~30 million KRW), and in the case of HBP there is a risk that the lead may be dropped out.
Our technology can access directly to ventricular septum of heart with a simple minimally invasive operation that impacting on the overall electrical conduction system of the heart. Technically, our ‘His Pacing’ and ‘Thru-Septal Pacing’ have vital role to deliver electrical impulse (signal) directly to the the His bundle, core axis of the cardiac conduction pathway, and vicinity.
|His Pacing||Cerclage Pacing|
|Target||His bundle and adjacent tissues||His bundle and adjacent tissues|
|Approach||Right atrium and right ventricle||Coronary sinus and ventricular septal veins|
|Applicable pacemaker leads||Only available with Medtronic's Select Secure 3830 lead||All leads of over the wire type can be used (Medtronic, Boston, St Jude, etc.)|
|Clinical Data||Holds Relatively Rich Clinical Data||Obtaining Initial Clinical Data|
|1. In 10-20% of patients, it is difficult to locate the lead by finding the appropriate point.
2. The high Pacing output causes shortening of the life of the pacemaker battery.
1. General surgeons need education on the procedure as a new approach to treatment
2. In addition to the pacemaker's general device tools, accessory devices necessary for the procedure are required (this is the company's development item) (this is the company's development item)
3. The procedure is affected by the septal vein structure.
|Positioning as a new alternative to pacemaker and ventricular synchronization therapy||Provides wider treatment opportunities as an alternative to other approaches for His pacing|